The groundbreaking rise of Viagra has consistently remained a benchmark of pharmaceutical success, however its future within the broader market now presents questions about future returns . Alternative versions are diminishing exclusivity , prompting anxieties that investing in companies heavily reliant to Viagra's former standing could be a danger